Clin Oncol (R Coll Radiol). 2016 Sep 24. pii: S0936-6555(16)30283-7. doi: 10.1016/j.clon.2016.08.016. [Epub ahead of print]

Moss EL¹, Taneja S², Munir F³, Kent C², Robinson L⁴, Potdar N², Sarhanis P⁵, McDermott H³.

Abstract

The ever-improving prognosis of women diagnosed with cervical cancer has meant that survivorship and treatment-related sequelae are being brought more into the spotlight in an attempt to try to reduce morbidity and improve women's long-term health. However, there are many issues surrounding an iatrogenic menopause in cervical cancer, a variety of potential management options and barriers to treatment. Women who have become menopausal under the age of 45 years as a result of cervical cancer are significantly less likely to start hormone replacement therapy (HRT) or continue it long term as compared with those who have undergone a surgical menopause for a benign reason. High profile media reports raising concerns about the safety of HRT use have left many women reluctant to consider HRT as a therapeutic option for menopausal symptoms and many are seeking to use complementary/alternative medicine, including non-pharmacological interventions, to alleviate symptoms. The benefits of HRT in this population have been shown to reduce these effects, although adherence to treatment regimens is a challenge due to poor compliance, which is in part due to the fear of a second malignancy. The development of non-HRT-based interventions to ameliorate menopausal symptoms and reduce the long-term health consequences are needed for women who choose not to take HRT.

資料來源：PubMed

連結網址:  https://www.ncbi.nlm.nih.gov/pubmed/27683104